Astria Therapeutics (ATXS) announced initiation of a Phase 1a clinical trial of STAR-0310 in healthy subjects. STAR-0310, a high affinity monoclonal antibody OX40 antagonist that incorporates YTE technology, is in development for the potential treatment of atopic dermatitis AD and potentially other indications. The Phase 1a trial is intended to assess the safety, tolerability, pharmacokinetics, and immunogenicity of STAR-0310 in healthy adult participants. Astria expects early proof-of-concept results from the Phase 1a trial in the third quarter of 2025. “The Phase 1a trial of STAR-0310 in healthy subjects is an important opportunity for us to clinically differentiate the profile of STAR-0310,” said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics. “We believe STAR-0310 will be the best-in-class therapy due to efficacy, safety and tolerability, and treatment burden, and could transform lives for many people living with moderate-to-severe AD.”
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATXS:
- Astria Therapeutics designs ALPHA-ORBIT Phase 3 trial of navenibart in HAE
- Astria Therapeutics Unveils Phase 3 Trial for Navenibart
- Astria Therapeutics Expands Stock Incentive Plan
- Astria Therapeutics price target raised to $32 from $28 at Oppenheimer
- Astria Therapeutics announces final results from ALPHA-STAR trial